Education Department Spring 2023 Activities
The 2023 application season is coming to a close with a very competitive applicant pool. Read more about highlights and upcoming events.
The 2023 application season is coming to a close with a very competitive applicant pool. Read more about highlights and upcoming events.
Scientists at SENS Research Foundation led by Dr. Tesfahun (Tes) Dessale Admasu have just published their exciting new senolytic strategy to destroy a wider range of senescent cells than has up to now been possible.
SRF is a proud sponsor of LessDeath and the Longevity Summer Camp! LessDeath is a new organization and event series dedicated to helping people join the Longevity Biotechnology industry through education, career and community strategizing, job opportunities, and more.
Invitation for Dr. De Grey and Richard Heart to join the Board of Directors
We are proud to announce the recent publication by Sharma lab/ApoptoSENS team in the journal Cells describing the role and controversies involving the aging of Natural Killer (NK) cells and age-related NK cell dysfunction. This review focuses on recent advances and open questions in understanding the interplay between systemic inflammation, senescence burden, and NK cell dysfunction in the context of aging and potential therapies for age-related diseases.
We are pleased to announce that the ApoptoSENS team led by Dr. Amit Sharma at the SRF Research Center has recently been granted a Catalyst award, courtesy of the Healthy Longevity Global Competition, to continue and expand their critical work on the interactions between senescent cells and natural killer (NK) cells.
We’re delighted to announce that SRF’s Chief Science Officer Dr. Aubrey de Grey has been awarded the 2020 Bacon Prize for Thought Leadership in Super Longevity at this year’s RAADfest.
We’re inviting all our supporters to submit designs for an official SRF mask. As well as being worn by our staff, these masks will be available in limited supply to anyone who’d like to support our work to end age-related disease and disability.
SRF spin-off Revel Pharmaceuticals, a privately held biotechnology company creating therapeutics to reverse and repair damage that results from aging – particularly extracellular crosslinks – has announced recent additions to its Board of Directors and Scientific Advisory Board.